Regenxbio Faces Investor Lawsuits and Regulatory Hurdles

Regenxbio stock plunges 42% amid lawsuits alleging it concealed safety issues in a gene therapy trial, compounded by FDA clinical holds and a rejection.

The biotechnology firm Regenxbio is now confronting a surge of class-action lawsuits. Legal proceedings initiated this Monday allege that company leadership violated securities laws. Central to the claims is the accusation that Regenxbio concealed significant safety concerns during the development of one of its gene therapies.

Stock Decline and Investor Confidence

This development has severely shaken investor confidence. Regenxbio shares are currently trading at 6.75 euros, reflecting a dramatic loss of over 42 percent in value during the past month alone. This steep decline places the stock perilously close to its 52-week low.

The legal challenges focus on the period spanning February 2022 to January 2026. Plaintiffs contend that Regenxbio issued misleading statements regarding the safety and efficacy of its drug candidate RGX-111, which is being developed to treat Hurler syndrome. A particularly serious allegation is that the company failed to disclose in a timely or adequate manner the discovery of a tumor in the central nervous system of a clinical trial participant.

FDA Actions Compound Difficulties

These lawsuits follow a series of regulatory setbacks from the U.S. Food and Drug Administration (FDA). In late January, the health authority imposed a clinical hold on both the RGX-111 and RGX-121 programs. This decision was based on a preliminary analysis of the reported tumor case, with the FDA identifying potential risks for both studies due to similarities in their protocols.

Furthermore, in early February, the FDA issued a Complete Response Letter, declining for now to approve the application for RGX-121. Regulators expressed concerns about the definition of the patient population and the comparability of the control data used in the submission.

Pipeline Focus Shifts to RGX-202

Amid these challenges with its MPS therapies, can Regenxbio's remaining pipeline assets restore the substantial trust lost in recent weeks? Company management is now highlighting progress with RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. Recent positive long-term data from an early-stage study have been released for this candidate.

The coming months are set to be decisive for the company's direction. Regenxbio anticipates reporting crucial topline data for RGX-202 at the start of the second quarter of 2026. A positive outcome would pave the way for the company to submit an application for accelerated approval by mid-year. Concurrently, management aims to meet with the FDA to discuss a potential path forward for resuming the clinically halted programs.